Safety Evaluation Of Pegaspargase And L-Asparaginase In Treatment Of Adult Acute Lymphoblastic Leukemia

Objective: Pegaspargase and L-asparaginase in the treatment of adult acute lymphoblastic leukemia(ALL)in the evaluation of its safety to provide relevant evidence for the clinical use of drugs.Methods:60 cases of newly diagnosed acute lymphoblastic leukemia and BCR-ABL fusion gene-negative cases were collected from our department,retrospective analysis of the medical records of the above patients.The effect of complete remission(CR)was analyzed and compared between the group patients with PEG-ASP or L-ASP(34)and control group.The changes of coagulation in patients with PEG-ASP group and L-ASP group were compared with the occurrence of adverse reactions such as liver function abnormalities,allergies,hyperglycemia,abnormal blood amylase,and urinary lipase.Results:Influence on coagulation function,After using peg-asp or l-asp group and the control group,INR(1.26±0.27,1.14±0.18),APTT(46.76±12.20,39.75±8.20),FIB(2.37±1.76,3.58±2.14).After using PEG-ASP or L-ASP INR(1.32±0.31,1.16±0.15),APTT(47.40±12.97,45.77±11.34),FIB(2.07±1.57,2.83±2.00).Respect ively,the P values of the two groups were 0.07,0.02 and 0.02.The patients with PEG-ASP and L-ASP had abnormal liver function after treatment.There were 5 cases(25.0%)in PEG-ASP groups and 6 cases(42.9%)in L-ASP groups.Between the two groups,between the two groups there was no significant difference(P = 0.21).No allergy,hyperglycemia,abnormal blood amylase and urinary lipase were found in both groups after treatment.Conclusion:1.PEG-ASP and L-ASP caused INR,APTT prolongation and FIB decreased,between the two groups there were no significant difference.2.Both PEG-ASP and L-ASP can cause liver dysfunction,but they have no statistical difference 3.PEG-ASP and L-ASP did not cause elevated blood glucose,blood amylase and urinary lipase abnormalities.